OBJECTIVE: Assessment of the effectiveness of constraint-induced (CI) movement therapy and quantitative evaluation of the effects of CI therapy. DESIGN: Intervention study; case series; pretreatment to posttreatment measures and follow-up 3 months after intervention. SETTING: An outpatient department. PATIENTS: Five chronic stroke patients with moderate motor deficit; convenience sample. INTERVENTIONS: CI therapy consisting of restraint of the unaffected upper extremity in a sling for 14 days combined with 6 hours of training per weekday of the affected upper extremity. MAIN OUTCOME MEASURES: Actual Amount of Use Test (AAUT), Motor Activity Log (MAL), Wolf Motor Function Test (WMFT), and Arm Motor Ability Test (AMAT) RESULTS: There was a substantial improvement in the performance times of the laboratory tests (AMAT, WMFT, p < or = .039) and in the quality of movement (AMAT, WMFT, p < or = .049; MAL, p = .049), particularly in the use of the extremity in "real world" environments (AAUT, p = .020), supported by results of quantitative evaluation. The effect sizes were large and comparable to those found in previous studies of CI therapy. CONCLUSIONS: CI therapy is an efficacious treatment for chronic stroke patients, especially in terms of real world outcome.
OBJECTIVE: Assessment of the effectiveness of constraint-induced (CI) movement therapy and quantitative evaluation of the effects of CI therapy. DESIGN: Intervention study; case series; pretreatment to posttreatment measures and follow-up 3 months after intervention. SETTING: An outpatient department. PATIENTS: Five chronic strokepatients with moderate motor deficit; convenience sample. INTERVENTIONS: CI therapy consisting of restraint of the unaffected upper extremity in a sling for 14 days combined with 6 hours of training per weekday of the affected upper extremity. MAIN OUTCOME MEASURES: Actual Amount of Use Test (AAUT), Motor Activity Log (MAL), Wolf Motor Function Test (WMFT), and Arm Motor Ability Test (AMAT) RESULTS: There was a substantial improvement in the performance times of the laboratory tests (AMAT, WMFT, p < or = .039) and in the quality of movement (AMAT, WMFT, p < or = .049; MAL, p = .049), particularly in the use of the extremity in "real world" environments (AAUT, p = .020), supported by results of quantitative evaluation. The effect sizes were large and comparable to those found in previous studies of CI therapy. CONCLUSIONS: CI therapy is an efficacious treatment for chronic strokepatients, especially in terms of real world outcome.
Authors: Kathleen M Friel; Scott Barbay; Shawn B Frost; Erik J Plautz; Ann M Stowe; Numa Dancause; Elena V Zoubina; Randolph J Nudo Journal: Neurorehabil Neural Repair Date: 2007 Jan-Feb Impact factor: 3.919
Authors: Ela Bhatt; Ashima Nagpal; Kristine H Greer; Tiffany K Grunewald; Jennifer L Steele; Jeff W Wiemiller; Scott M Lewis; James R Carey Journal: Exp Brain Res Date: 2007-06-12 Impact factor: 1.972
Authors: Sunghoon I Lee; Catherine P Adans-Dester; Matteo Grimaldi; Ariel V Dowling; Peter C Horak; Randie M Black-Schaffer; Paolo Bonato; Joseph T Gwin Journal: IEEE J Transl Eng Health Med Date: 2018-05-02 Impact factor: 3.316
Authors: Edward Taub; Gitendra Uswatte; Victor W Mark; David M Morris; Joydip Barman; Mary H Bowman; Camille Bryson; Adriana Delgado; Staci Bishop-McKay Journal: Stroke Date: 2013-03-21 Impact factor: 7.914